Shielding the ovaries: a drug may help young breast cancer patients preserve fertility during chemo

NCT ID NCT07127315

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial tests whether giving goserelin, a hormone-blocking drug, alongside chemotherapy can help preserve ovarian function and fertility in premenopausal women with breast cancer. Participants receive either chemotherapy plus goserelin or chemotherapy alone. Researchers will measure hormone levels and long-term outcomes like disease-free and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Goserelin, a gonadotropin-releasing hormone agonist, given alongside chemotherapy
What this could lead to
If effective, this approach could help preserve fertility and ovarian function in young breast cancer patients undergoing chemotherapy.
What could go wrong
The trial is relatively small and early, and results may not apply to all patients. Goserelin has side effects and may not fully protect ovarian function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Helwan University

    Helwan, Helwan, 11795, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.